Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancer
First HER2-directed medicine approved for patients with gastric cancer in a decadeAstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving beyond five years.[1,2] Approximately one in five gastric